Zobrazeno 1 - 10
of 11
pro vyhledávání: '"J F, Hoke"'
Publikováno v:
European journal of clinical pharmacology. 55(11-12)
Objective: The objective of this study was to characterize the pharmacokinetics of gavestinel in patients with acute stroke. Methods: Gavestinel was administered as an 800-mg loading dose and followed by either 100-, 200-, or 400-mg maintenance doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b01fb6284825844a06f6b6c6c8ad541
https://pubmed.ncbi.nlm.nih.gov/10805066
https://pubmed.ncbi.nlm.nih.gov/10805066
Publikováno v:
Journal of clinical pharmacology. 39(6)
The utility of interspecies scaling in early drug development has been extensively debated. The authors discuss the dose selection strategy for a first time into man (FTIM) study for GV196771, a new glycine antagonist, using techniques of interspecie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137c4f0872b81cbc153c3aabc33763c1
https://pubmed.ncbi.nlm.nih.gov/10354959
https://pubmed.ncbi.nlm.nih.gov/10354959
Publikováno v:
Pharmaceutical research. 14(12)
The goal of this study was to determine if the co-administration of esmolol (ES), a short acting cardioselective beta-blocker, significantly alters the pharmacokinetics and/or pharmacodynamics of remifentanil (REMI), an ultra short-acting opioid, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c475bea2a62b93152f46d73e508f92b1
https://pubmed.ncbi.nlm.nih.gov/9453074
https://pubmed.ncbi.nlm.nih.gov/9453074
Autor:
J F, Hoke, D, Shlugman, M, Dershwitz, P, Michałowski, S, Malthouse-Dufore, P M, Connors, D, Martel, C E, Rosow, K T, Muir, N, Rubin, P S, Glass
Publikováno v:
Anesthesiology. 87(3)
Remifentanil is an opioid analgesic for use in anesthesia. An ester linkage renders it susceptible to rapid metabolism by blood and tissue esterases. Thus it was hypothesized that remifentanil elimination would be independent of renal function. Becau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a85cd6c73ca43e497cae0fd8e6e3ec55
https://pubmed.ncbi.nlm.nih.gov/9316957
https://pubmed.ncbi.nlm.nih.gov/9316957
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 281(1)
Remifentanil is an esterase-metabolized opioid developed for use in anesthesia. The principal metabolite of remifentanil, GR90291, is considered to be less potent. This study determined the relative potency of GR90291 and alfentanil, compared with re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a71cf666741c76b2ca90ea56988637e
https://pubmed.ncbi.nlm.nih.gov/9103501
https://pubmed.ncbi.nlm.nih.gov/9103501
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 21(3)
14C-labeled vigabatrin (50 microCi), an antiepileptic drug, was administered to six healthy male volunteers as a single oral dose containing 1500 mg of vigabatrin to determine the disposition profile of 14C and parent drug, and to investigate the met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cd569cbcb17e8a6ed7604da0204d8e1d
https://pubmed.ncbi.nlm.nih.gov/8100505
https://pubmed.ncbi.nlm.nih.gov/8100505
Autor:
J F, Hoke, W R, Ravis
Publikováno v:
Research communications in chemical pathology and pharmacology. 73(3)
Perfluorochemical (PFC) emulsions have recently been investigated for use in the treatment of various clinical conditions requiring red blood cell replacement. The physiological changes which develop following PFC infusion may directly, or indirectly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::be63b01b3f1abb852559292abe827cd7
https://pubmed.ncbi.nlm.nih.gov/1947444
https://pubmed.ncbi.nlm.nih.gov/1947444
Publikováno v:
Research communications in chemical pathology and pharmacology. 73(3)
Perfluorochemical (PFC) emulsions have been examined for use as erythrocyte substitutes in the treatment of various disease states. The physiological changes induced by PFC infusion would be an important determinant of successful clinical therapy. Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::208330fc68a588dd4307414d8440821f
https://pubmed.ncbi.nlm.nih.gov/1719593
https://pubmed.ncbi.nlm.nih.gov/1719593
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P97-P97
Background/Aims Ondansetron (OND) is indicated in patients as young as 2 yr of age for the prevention of nausea and vomiting. There is an unmet need for antiemetic therapy in very young oncology and surgical patients, and off-label use of OND in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b2374dc18f523c53bcc50075807fa13
https://doi.org/10.1016/j.clpt.2005.01.002
https://doi.org/10.1016/j.clpt.2005.01.002
Autor:
Carl E. Rosow, S Dufore, D. Shlugman, Keith T. Muir, Piotr Michalowski, Mark Dershwitz, J. F. Hoke, Peter S. A. Glass
Publikováno v:
Anesthesiology. 81:A1418
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::430fece081b11e1b62b1ddade7eae0a9
https://doi.org/10.1097/00000542-199409001-01417
https://doi.org/10.1097/00000542-199409001-01417